IP Library Granted Patent US 8,703,152
Granted Patent B2
US 8,703,152 · App. 12/996,166 · Granted Apr 22, 2014

Methods of treating inflammatory intestinal disease and managing symptoms thereof

Inventor: Jun Sun (Rochester, NY)
Assignee: University of Rochester
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,703,152
App. No.
12/996,166
Granted
Apr 22, 2014
Kind
B2
Abstract

Methods and products are disclosed for treating an inflammatory intestinal disease in a mammalian subject in need thereof, or preventing or reducing a symptom of inflammatory intestinal disease. These method include administering to the subject a therapeutically effective dose of (i) an isolated AvrA protein or polypeptide fragment thereof or (ii) a nucleic acid molecule encoding the isolated AvrA protein or polypeptide fragment. Preferred inflammatory intestinal diseases include Inflammatory Bowel Disease, Celiac Disease, and gastroenteritis.

Claims (8)

1. A method for treating inflammatory intestinal disease or disorder in a mammalian subject in need thereof, the method comprising: administering to the subject a therapeutically effective dose of an isolated AvrA protein or polypeptide comprising an amino acid sequence that is at least about 90% identical to the full length of SEQ ID NO: 19.

2. The method of claim 1 , wherein the inflammatory intestinal disease or disorder is Inflammatory Bowel Disease, Celiac Disease, or gastroenteritis.

3. The method of claim 1 , wherein the AvrA protein is a Salmonella AvrA protein.

4. The method of claim 1 , wherein the AvrA protein or polypeptide is administered at a dose ranging from 0.1 mg to 10 mg of said protein or polypeptide per kg of said subject's body weight.

5. The method of claim 1 , wherein said administering is carried out parenterally, orally, topically, intranasally, rectally, or via slow releasing microcarriers.

6. The method of claim 1 , wherein the isolated AvrA protein or polypeptide is present in a composition further comprising a stabilizing agent.

7. The method of claim 1 , wherein the isolated AvrA protein or polypeptide comprises an amino acid sequence that is at least about 95% identical to the full length of SEQ ID NO: 19.

8. The method of claim 1 , wherein the isolated AvrA protein or polypeptide comprises an amino acid sequence that is at least about 97% identical to the full length of SEQ ID NO: 19.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 5, 2012
From: UNIVERSITY OF ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028914/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2011
From: SUN, JUN
To: UNIVERSITY OF ROCHESTER
Reel/Frame 026156/0384 →
Continuity (2)
Provisional Application 61058421 · Jun 3, 2008
Related Publication 20110178030A1 · Jul 21, 2011